News|Articles|November 18, 2026

Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS

Fact checked by: Chelsie Derman
Listen
0:00 / 0:00

Key Takeaways

  • Omalizumab demonstrated the highest anaphylaxis reporting proportion in FAERS, whereas dupilumab showed the lowest among established agents, despite substantial report volumes for both therapies.
  • Reslizumab and tezepelumab followed omalizumab in anaphylaxis reporting proportions, supporting agent-level heterogeneity that may reflect indication mix, market time, and reporting behavior.
SHOW MORE

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab anchor biologic treatment for severe asthma and related type 2 respiratory disease. Additionally, the FDA approved depemokimab, the first biologic with twice-yearly dosing, in December 2025.¹ Comparative postmarketing data on anaphylaxis across these agents remain limited, with prior FAERS work largely focused on individual drugs or pairwise comparisons. A 2021 disproportionality analysis of FAERS reports from 2004 through 2021 identified a positive anaphylaxis signal for omalizumab (reporting odds ratio, 2.24; 95% CI, 2.18-2.29) and a negative signal for dupilumab.²

A retrospective pharmacovigilance analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix examined FAERS reports for 7 respiratory biologics from October 1, 2020, through March 31, 2026.³ Omalizumab had the highest anaphylaxis reporting proportion across all indications and among reports with respiratory indications, followed by reslizumab and tezepelumab.³ Dupilumab had the lowest proportions among the 6 established agents.3

Because FAERS lacks exposure denominators, these figures reflect the share of adverse-event reports involving anaphylaxis rather than incidence among treated patients.³ Jennifer K. Priessnitz, MD, a resident at Macon & Joan Brock Virginia Health Sciences at Old Dominion University, presented the oral abstract during the meeting. In the following Q&A, Priessnitz discusses the rationale for the comparison, how her team identified anaphylaxis reports, and the agent-level reporting patterns observed.

Q&A: Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS

HCPLive: What is the main takeaway from this analysis for allergists and pulmonologists who prescribe respiratory biologics?

Jennifer K. Priessnitz, MD: The primary takeaway is that anaphylaxis reporting patterns vary across respiratory biologics, highlighting the importance of continued postmarketing safety surveillance.

In our analysis of 7 respiratory biologics, omalizumab demonstrated the highest anaphylaxis reporting proportion, both across all clinical indications (5.95%) and among reports containing respiratory clinical indications (4.45%). In contrast, dupilumab demonstrated the lowest reporting proportions among the six established biologics, at 0.15% and 0.31%, respectively.

Both omalizumab and dupilumab had substantial reporting populations, with more than 40,000 and 360,000 adverse-event reports, respectively. These large sample sizes provide relatively precise estimates of their respective reporting proportions, as reflected by narrow 95% confidence intervals, and strengthen our ability to characterize reporting patterns for these agents. However, reporting volume does not necessarily translate into greater certainty regarding actual clinical risk.

It is important to emphasize that these findings represent the proportion of adverse-event reports involving anaphylaxis, rather than the incidence of anaphylaxis among patients receiving these medications. Differences in prescribing patterns, patient populations, duration of market availability, and reporting behavior may all influence these findings.

Our results reinforce the importance of understanding the established safety profiles of individual biologics, counseling patients regarding potential hypersensitivity reactions, and maintaining appropriate monitoring practices. These findings should be viewed as hypothesis-generating rather than evidence that 1 biologic carries a greater or lesser clinical risk of anaphylaxis.

HCPLive: What gap in the postmarketing safety literature led your team to compare anaphylaxis reporting across respiratory biologics now?

Jennifer K. Priessnitz, MD: Biologic therapies have transformed the management of severe asthma and other chronic respiratory diseases, with newer agents such as tezepelumab and depemokimab expanding treatment options through distinct inflammatory pathways. As their use continues to increase, understanding their postmarketing safety profiles becomes increasingly important. Although anaphylaxis is a recognized but uncommon adverse event associated with certain biologics, comparative safety data remain limited, with much of the existing literature focused on individual agents rather than comparisons across therapies.

An important motivation for our study was the association between poorly controlled asthma and more severe outcomes during anaphylaxis, particularly when respiratory compromise occurs. Given that many respiratory biologics are prescribed for patients with severe or uncontrolled asthma, we wanted to investigate whether anaphylaxis reporting proportions differed among reports containing respiratory clinical indications compared with reports across all clinical indications.

Our goal was to address this gap by providing a contemporary comparison of anaphylaxis reporting patterns across 7 respiratory biologics, including newer agents, while examining whether underlying treatment indications might influence observed reporting patterns. We hoped to identify areas warranting further investigation and contribute to a more comprehensive understanding of the postmarketing safety profiles of these increasingly utilized therapies.

HCPLive: How did you use FAERS to compare agents, and how did you define and identify anaphylaxis cases?

Jennifer K. Priessnitz, MD: We conducted a retrospective pharmacovigilance analysis using publicly available case-level data from the FDA Adverse Event Reporting System (FAERS), accessed through the FDA Adverse Event Monitoring System dashboard. Our analysis included reports from October 1, 2020, through March 31, 2026, involving 7 biologics used in respiratory disease: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and depemokimab. For depemokimab, we restricted the analysis to reports received following FDA approval.

We identified reports using the biologics’ generic and brand names and defined anaphylaxis using prespecified MedDRA reaction terms: anaphylaxis, anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, and anaphylactoid shock. Reports were deduplicated by Case ID to minimize duplicate counting.

For each biologic, we calculated the anaphylaxis reporting proportion by dividing the number of reports containing a qualifying anaphylaxis term by the total number of adverse-event reports associated with that biologic. We calculated Wilson 95% confidence intervals and performed a separate analysis among reports containing qualifying respiratory clinical indications, including asthma, chronic rhinosinusitis with nasal polyps, chronic sinusitis, COPD, and eosinophilic granulomatosis with polyangiitis.

HCPLive: Which biologics showed the strongest anaphylaxis reporting signals, and did any differences between agents surprise you?

Jennifer K. Priessnitz, MD: Omalizumab demonstrated the highest observed anaphylaxis reporting proportion at 5.95% across all clinical indications and 4.45% among reports containing respiratory clinical indications. Reslizumab had the second-highest reporting proportions at 2.65% overall and 2.36% in the respiratory subgroup, followed by tezepelumab at approximately 1.31% and 1.34%, respectively. Dupilumab demonstrated the lowest reporting proportions among the six established biologics, at 0.15% overall and 0.31% in the respiratory subgroup.

The relatively elevated reporting proportion for omalizumab was not entirely unexpected, given its established association with anaphylaxis and the longstanding recognition of this adverse event in clinical practice. However, increased awareness of a known safety concern may itself influence spontaneous reporting.

One particularly interesting finding was that restricting the analysis to respiratory clinical indications did not consistently increase anaphylaxis reporting proportions across agents. For example, dupilumab’s reporting proportion was approximately twice as high in the respiratory subgroup compared with its overall reporting proportion, whereas omalizumab demonstrated a lower proportion in the respiratory subgroup.

These differences suggest that the distribution of reported adverse events may vary by treatment indication and patient population. However, they should not be interpreted as evidence that respiratory disease independently increases anaphylaxis risk.

We also identified no anaphylaxis reports among 3 post-approval depemokimab adverse event reports, although this sample was far too small to draw meaningful safety conclusions.

References

  1. Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma. GSK. Published December 16, 2025. Accessed November 18, 2026. https://www.businesswire.com/news/home/20251216764904/en/Exdensur-depemokimab-approved-by-US-FDA-for-the-treatment-of-severe-asthma
  2. Bian S, Zhang P, Li L, et al. Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 2021;12:767999. doi:10.3389/fphar.2021.767999
  3. Priessnitz JK. Comparative postmarketing analysis of anaphylaxis with respiratory biologics using the FDA Adverse Event Reporting System. Presented at: American College of Allergy, Asthma and Immunology Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.

Related to this article